Retension Pharmaceuticals Announces Pricing of Initial Public Offering

Summary

Retension Pharmaceuticals priced its IPO at $12.00 per share with gross proceeds of $45.0 million, with shares expected to begin trading on Nasdaq under ticker RTSN on October 9, 2026. The offering is expected to close on October 13, 2026.